Verve TherapeuticsVERV
VERV
About: Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
Employees: 274
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
22% more capital invested
Capital invested by funds: $364M [Q3] → $444M (+$79.7M) [Q4]
17% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 54
4.06% more ownership
Funds ownership: 88.86% [Q3] → 92.92% (+4.06%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
4% less funds holding
Funds holding: 173 [Q3] → 166 (-7) [Q4]
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
21% less call options, than puts
Call options by funds: $734K | Put options by funds: $926K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$15
227%
upside
Avg. target
$26
461%
upside
High target
$39
750%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Etzer Darout 15% 1-year accuracy 5 / 33 met price target | 423%upside $24 | Buy Maintained | 15 Apr 2025 |
Canaccord Genuity Whitney Ijem 25% 1-year accuracy 11 / 44 met price target | 750%upside $39 | Buy Maintained | 15 Apr 2025 |
HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 57 / 186 met price target | 445%upside $25 | Buy Maintained | 14 Apr 2025 |
RBC Capital Luca Issi 7% 1-year accuracy 4 / 55 met price target | 227%upside $15 | Outperform Maintained | 4 Mar 2025 |
Financial journalist opinion
Based on 9 articles about VERV published over the past 30 days
Positive
The Motley Fool
18 hours ago
Why Verve Therapeutics Zoomed 40% Higher This Week
Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics' (VERV 2.00%) big stock price leap this week. By the time the dust cleared, the biotech company's shares soared 40% higher over the period, according to data compiled by S&P Global Market Intelligence.
Positive
Seeking Alpha
3 days ago
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'
VERV's VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102's development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV's pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly.
Positive
Zacks Investment Research
3 days ago
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
Verve Therapeutics stock rises on demonstrating superior LDL-C lowering ability in a phase Ib study of VERVE-102 in patients with HeFH and/or CAD.
Positive
The Motley Fool
4 days ago
Why Verve Therapeutics Is Skyrocketing Today
Verve Therapeutics (VERV 22.57%) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m.
Positive
Benzinga
5 days ago
Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose
Verve Therapeutics Inc VERV on Monday released initial data from the Heart-2 Phase 1b trial of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD), which requires reducing low-density lipoprotein cholesterol (LDL-C) levels in the blood.
Neutral
GlobeNewsWire
5 days ago
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort
Neutral
GlobeNewsWire
1 week ago
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VERVE-102 for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein cholesterol (LDL-C). VERVE-102 is the company's novel, in vivo, investigational base editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces disease-driving LDL-C. VERVE-102 is currently being tested in the Phase 1b Heart-2 clinical trial, which is designed to evaluate the safety and tolerability of VERVE-102 administration in adult patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD) who require additional lowering of LDL-C.
Neutral
GlobeNewsWire
2 weeks ago
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31, 2025, the company granted equity awards to three new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
3 weeks ago
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for VERVE-102 for the treatment of patients living with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). VERVE-102 is a novel, investigational in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood low-density lipoprotein cholesterol (LDL-C).
Neutral
GlobeNewsWire
1 month ago
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on February 28, 2025, the company granted equity awards to four new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™